FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004644923> ?p ?o ?g. }

• W2004644923 endingPage "1363" @default.
• W2004644923 startingPage "1358" @default.
• W2004644923 abstract "For patients with chronic myeloid leukemia (CML), long-term survival after stem cell transplantation requires adequate control of graft-versus-host disease (GVHD) and disease recurrence. Relapsing patients respond to donor lymphocyte infusion (DLI) but develop life-threatening complications.Patients with CML in first chronic phase received bone marrow (n = 14) or peripheral blood progenitor cell transplants (n = 4) from HLA-identical siblings. GVHD prophylaxis was by ex vivo T-cell depletion with CAMPATH 1G. If disease recurred, donors' mononuclear cells were collected by apheresis, the CD3 samples commencing at 10(6)/kg were aliquoted at half-log increment intervals, cryopreserved, and infused until disease clearance.Eighteen patients (median age: 32.5 years) received transplants. All engrafted without procedure-related mortality. Fourteen patients relapsed, and 13 entered the DLI program. Two developed extensive GVHD after single schedule infusions ranging from 89x10(6) to 670x10(6) mononuclear cells/kg, and one survives in complete remission (CR). The rest, treated with incremental dose DLI, experienced no acute toxicities. One, who had developed grade III steroid-responsive GVHD, died in CR2 from opportunistic infections. Steroids reversed limited cutaneous GVHD and elevated liver enzymes in five patients. Three others developed pancytopenia, and two restored blood counts only after donor peripheral blood progenitor cell infusions. Molecular CR2 was established in 12/13 patients, occurring in 10/11 (91%) on the incremental program at a median accumulation of 67 (range: 5-166) x10(6) CD3 cells/kg. Sixteen of 18 (89%) survive at median of 854.5 days from bone marrow transplantation, 4 in CR1 and 10 in CR2 at a median disease-free survival (for remission 2) duration of 341 days. The median combined disease-free survival of the 14 patients in CR 1+2 is 660 days, with 99% average performance status.Escalating DLI leads to safe new molecular CR in most CML relapse patients. These results raise the possibility of using safe transplantation programs of T-cell depletion, that include graded DLI as prevention against disease recurrence." @default.
• W2004644923 created "2016-06-24" @default.
• W2004644923 creator A5005355990 @default.
• W2004644923 creator A5042813915 @default.
• W2004644923 creator A5052428792 @default.
• W2004644923 creator A5060292533 @default.
• W2004644923 creator A5089726406 @default.
• W2004644923 date "2000-04-01" @default.
• W2004644923 modified "2023-09-25" @default.
• W2004644923 title "BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS FOLLOWED BY REPLETION WITH INCREMENTAL DOSES OF DONOR LYMPHOCYTES FOR RELAPSING PATIENTS WITH CHRONIC MYELOID LEUKEMIA" @default.
• W2004644923 cites W1479909146 @default.
• W2004644923 cites W1504399806 @default.
• W2004644923 cites W1545991364 @default.
• W2004644923 cites W1707184873 @default.
• W2004644923 cites W175951554 @default.
• W2004644923 cites W193514409 @default.
• W2004644923 cites W1972999362 @default.
• W2004644923 cites W1983916012 @default.
• W2004644923 cites W1995133626 @default.
• W2004644923 cites W2002024986 @default.
• W2004644923 cites W2009468472 @default.
• W2004644923 cites W2014996238 @default.
• W2004644923 cites W2027359481 @default.
• W2004644923 cites W2053278212 @default.
• W2004644923 cites W2054448483 @default.
• W2004644923 cites W2074943380 @default.
• W2004644923 cites W2094292853 @default.
• W2004644923 cites W2101934730 @default.
• W2004644923 cites W2117581174 @default.
• W2004644923 cites W2167541030 @default.
• W2004644923 cites W2246362970 @default.
• W2004644923 cites W2784027154 @default.
• W2004644923 cites W3112353337 @default.
• W2004644923 cites W4243462000 @default.
• W2004644923 cites W4246085869 @default.
• W2004644923 cites W44995847 @default.
• W2004644923 cites W53690666 @default.
• W2004644923 doi "https://doi.org/10.1097/00007890-200004150-00025" @default.
• W2004644923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10798754" @default.
• W2004644923 hasPublicationYear "2000" @default.
• W2004644923 type Work @default.
• W2004644923 sameAs 2004644923 @default.
• W2004644923 citedByCount "26" @default.
• W2004644923 countsByYear W20046449232012 @default.
• W2004644923 countsByYear W20046449232013 @default.
• W2004644923 crossrefType "journal-article" @default.
• W2004644923 hasAuthorship W2004644923A5005355990 @default.
• W2004644923 hasAuthorship W2004644923A5042813915 @default.
• W2004644923 hasAuthorship W2004644923A5052428792 @default.
• W2004644923 hasAuthorship W2004644923A5060292533 @default.
• W2004644923 hasAuthorship W2004644923A5089726406 @default.
• W2004644923 hasBestOaLocation W20046449231 @default.
• W2004644923 hasConcept C126322002 @default.
• W2004644923 hasConcept C137061746 @default.
• W2004644923 hasConcept C141071460 @default.
• W2004644923 hasConcept C201750760 @default.
• W2004644923 hasConcept C202751555 @default.
• W2004644923 hasConcept C203014093 @default.
• W2004644923 hasConcept C2778461978 @default.
• W2004644923 hasConcept C2778729363 @default.
• W2004644923 hasConcept C2779382419 @default.
• W2004644923 hasConcept C2779695342 @default.
• W2004644923 hasConcept C2779972918 @default.
• W2004644923 hasConcept C2780007613 @default.
• W2004644923 hasConcept C28328180 @default.
• W2004644923 hasConcept C2911091166 @default.
• W2004644923 hasConcept C54355233 @default.
• W2004644923 hasConcept C55493867 @default.
• W2004644923 hasConcept C71924100 @default.
• W2004644923 hasConcept C86803240 @default.
• W2004644923 hasConcept C90924648 @default.
• W2004644923 hasConceptScore W2004644923C126322002 @default.
• W2004644923 hasConceptScore W2004644923C137061746 @default.
• W2004644923 hasConceptScore W2004644923C141071460 @default.
• W2004644923 hasConceptScore W2004644923C201750760 @default.
• W2004644923 hasConceptScore W2004644923C202751555 @default.
• W2004644923 hasConceptScore W2004644923C203014093 @default.
• W2004644923 hasConceptScore W2004644923C2778461978 @default.
• W2004644923 hasConceptScore W2004644923C2778729363 @default.
• W2004644923 hasConceptScore W2004644923C2779382419 @default.
• W2004644923 hasConceptScore W2004644923C2779695342 @default.
• W2004644923 hasConceptScore W2004644923C2779972918 @default.
• W2004644923 hasConceptScore W2004644923C2780007613 @default.
• W2004644923 hasConceptScore W2004644923C28328180 @default.
• W2004644923 hasConceptScore W2004644923C2911091166 @default.
• W2004644923 hasConceptScore W2004644923C54355233 @default.
• W2004644923 hasConceptScore W2004644923C55493867 @default.
• W2004644923 hasConceptScore W2004644923C71924100 @default.
• W2004644923 hasConceptScore W2004644923C86803240 @default.
• W2004644923 hasConceptScore W2004644923C90924648 @default.
• W2004644923 hasIssue "7" @default.
• W2004644923 hasLocation W20046449231 @default.
• W2004644923 hasLocation W20046449232 @default.
• W2004644923 hasLocation W20046449233 @default.
• W2004644923 hasOpenAccess W2004644923 @default.
• W2004644923 hasPrimaryLocation W20046449231 @default.
• W2004644923 hasRelatedWork W1974500257 @default.
• W2004644923 hasRelatedWork W1991433786 @default.

• next